Neumora Therapeutics, Inc. (NMRA): who owns it and who trades it
As of Nov 16, 2026, NMRA insiders reported 15 open-market sales worth $784K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Daljit Singh Aurora (See Remarks), with $723K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Neumora Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NMRA
112 funds and institutions reported NMRA shares worth $131M at the end of Q2 2026, about 42% of the company. The largest holder is Siren, L.L.C. with 4.7%.
Funds and institutions (13F) 42%Everyone else 58%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Siren, L.L.C. | 8.50M | 4.67% | $14.4M | No change |
| BlackRock, Inc. | 7.79M | 4.28% | $13.2M | +279% |
| Softbank Group Corp. | 6.09M | 3.35% | $10.4M | No change |
| Vanguard Capital Management LLC | 4.67M | 2.57% | $7.9M | +20% |
| MIC Capital Management UK LLP | 4.46M | 2.45% | $7.6M | No change |
| FMR LLC (Fidelity) | 3.50M | 1.92% | $5.9M | No change |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 3.31M | 1.82% | $5.6M | No change |
| Geode Capital Management, LLC | 2.61M | 1.43% | $4.4M | +140% |
| ICONIQ Capital, LLC | 2.56M | 1.41% | $4.4M | No change |
| Two Sigma Investments, LP | 2.24M | 1.23% | $3.8M | +10% |
| Orbimed Advisors LLC | 2.14M | 1.18% | $3.6M | – |
| Lunate Capital Ltd | 2.12M | 1.17% | $3.6M | No change |
| Boxer Capital Management, LLC | 2.00M | 1.10% | $3.4M | – |
| Johnson & Johnson | 1.85M | 1.02% | $3.1M | No change |
| State Street Corp | 1.58M | 0.87% | $2.7M | +297% |
| Tudor Investment Corp Et Al | 1.36M | 0.74% | $2.3M | +76% |
| Ikarian Capital, LLC | 1.28M | 0.70% | $2.2M | No change |
| Renaissance Technologies LLC | 1.26M | 0.69% | $2.1M | -9% |
| Affinity Asset Advisors, LLC | 1.07M | 0.59% | $1.8M | – |
| Marshall Wace, LLP | 904,458 | 0.50% | $1.5M | -24% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NMRA insiders reported $0 of open-market purchases and $784K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2026 | Daljit Singh Aurora | See Remarks | Sale | 20,553 | $1.59 | $32.7K | Form 4 |
| Aug 21, 2026 | Daljit Singh Aurora | See Remarks | Sale | 21,055 | $1.60 | $33.7K | Form 4 |
| Aug 20, 2026 | Daljit Singh Aurora | See Remarks | Sale | 66,711 | $1.51 | $101K | Form 4 |
| Aug 20, 2026 | Daljit Singh Aurora | See Remarks | Sale | 67,741 | $1.51 | $102K | Form 4 |
| Aug 19, 2026 | Daljit Singh Aurora | See Remarks | Sale | 30,918 | $1.65 | $51K | Form 4 |
| Aug 19, 2026 | Daljit Singh Aurora | See Remarks | Sale | 31,000 | $1.65 | $51.1K | Form 4 |
| Aug 18, 2026 | Daljit Singh Aurora | See Remarks | Sale | 34,987 | $1.59 | $55.6K | Form 4 |
| Aug 18, 2026 | Daljit Singh Aurora | See Remarks | Sale | 34,162 | $1.58 | $54K | Form 4 |
| Aug 17, 2026 | Daljit Singh Aurora | See Remarks | Sale | 55,016 | $1.50 | $82.5K | Form 4 |
| Aug 17, 2026 | Daljit Singh Aurora | See Remarks | Sale | 57,670 | $1.51 | $87.1K | Form 4 |
| Aug 17, 2026 | Daljit Singh Aurora | See Remarks | Sale | 34,020 | $1.49 | $50.7K | Form 4 |
| Feb 17, 2026 | Daljit Singh Aurora | See Remarks | Sale | 6,165 | $3.56 | $21.9K | Form 4 |
| Feb 17, 2026 | Joshua Pinto | President | Sale | 5,967 | $3.54 | $21.1K | Form 4 |
| Feb 17, 2026 | Paul L Berns | Director | Sale | 9,819 | $3.51 | $34.5K | Form 4 |
| Feb 17, 2026 | Michael Lee Milligan | See Remarks | Sale | 1,436 | $3.57 | $5.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Daljit Singh Aurora | See Remarks | – | $723K | Aug 21, 2026 |
| Paul L Berns | See Remarks, Director | – | $34.5K | Feb 17, 2026 |
| Joshua Pinto | President | – | $21.1K | Feb 17, 2026 |
| Michael Lee Milligan | See Remarks | – | $5.1K | Feb 17, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NMRA short interest
Low short interest. 3.7% of NMRA shares are sold short: about 1 share in 27. Over the last 12 reports the number of shares short went up 43%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.01M NMRA shares were sold short, 3.7% of the shares outstanding, up 24.2% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.01M | 3.73% | +24% | 1.37M | 5.1 |
| Oct 15, 2026 | 5.64M | 3.00% | -16% | 2.43M | 2.3 |
| Sep 30, 2026 | 6.69M | 3.56% | -4% | 2.49M | 2.7 |
| Sep 15, 2026 | 6.98M | 3.71% | -13% | 773,503 | 9.0 |
| Aug 31, 2026 | 8.03M | 4.27% | +0% | 788,846 | 10.2 |
| Aug 14, 2026 | 7.99M | 4.25% | +5% | 596,204 | 13.4 |
| Jul 31, 2026 | 7.62M | 4.19% | -2% | 692,473 | 11.0 |
| Jul 15, 2026 | 7.79M | 4.28% | +17% | 1.03M | 7.6 |
| Jun 30, 2026 | 6.68M | 3.67% | +36% | 6.01M | 1.1 |
| Jun 15, 2026 | 4.92M | 2.70% | -12% | 2.26M | 2.2 |
| May 29, 2026 | 5.58M | 3.07% | +14% | 1.11M | 5.0 |
| May 15, 2026 | 4.90M | 2.69% | +6% | 1.65M | 3.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Neumora Therapeutics company events
Neumora Therapeutics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Oct 30, 2026.
- Oct 30, 2026ListingNeumora Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Listing Rule 5450(a)(1). Filing
- Aug 14, 2026LeadershipThe Company announced that Paul L. Berns, the Company’s current Chief Executive Officer, will become the Company’s Executive Chairperson of the Board of Directors, and Joshua Pinto, Ph.D., the Company’s current President, will succeed Mr. Berns as the Company’s Chief Executive Officer effective… Filing
- Jul 27, 2026AnnouncementNeumora Therapeutics, Inc. issued a press release announcing favorable pre-clinical toxicology results from NMRA-215. Filing
- Jun 15, 2026AgreementNeumora Therapeutics, Inc. as borrower, entered into a Third Amendment to the Loan and Security Agreement, with K2 HealthVentures LLC as a lender, and the lenders party thereto from time to time (collectively, “Lenders”, and each, a “Lender”), and K2 HealthVentures LLC, as administrative agent for… Filing
- May 29, 2026VoteReported shareholder vote results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 30, 2026ResultsReleased financial results. Filing
- Feb 11, 2026AnnouncementShared information with investors. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 5, 2026AnnouncementNeumora Therapeutics, Inc. issued press releases announcing positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer’s disease (AD) agitation and key pipeline updates and anticipated 2026 milestones. Filing
- Nov 21, 2025SharesSold new shares outside a public offering. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Neumora Therapeutics financials
Famous investors that hold NMRA
4 of the 50 well-known investors we track reported holding NMRA in their latest 13F filing. The largest position is Jim Simons's, worth $674K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.13M | $674K | 0.0% | -11% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 1.03M | $613K | 0.0% | +24% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 631,091 | $376K | 0.0% | -53% |
| Israel Englander · Millennium Management | Q3 2026 | 328,544 | $196K | 0.0% | -35% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named NMRA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Paul L Berns | 13G/A | 5.4% |
| Nov 16, 2026 | Paul L Berns | 13G/A | 5.4% |
Questions about Neumora Therapeutics, Inc. (NMRA) stock
Who owns the most NMRA stock?
The largest reported owner of Neumora Therapeutics, Inc. (NMRA) is Siren, L.L.C., with 4.7% of the company. In total, 112 funds and institutions reported holding NMRA at the end of Q2 2026, together about 42% of the shares. See the largest owners.
Are NMRA insiders buying or selling?
In the last 12 months, NMRA insiders reported no open-market purchases and 15 sales worth $784K. The latest trade was on Aug 21, 2026. See every trade.
What is the short interest in NMRA?
As of Oct 30, 2026, 7.01M NMRA shares were sold short, 3.7% of the shares outstanding, up 24.2% from the report before. At the average daily volume of 1.37M shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold NMRA?
4 of the 50 well-known investors we track reported NMRA in their latest 13F filing, including Jim Simons, Ken Griffin, Paul Tudor Jones. The largest position is worth $674K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.